Hyderabad-based Suven Life Sciences has won four product patents for its new chemical entities designed for treatment of neurodegenerative diseases.
These were granted in Europe, Sri Lanka and South Korea for compounds that are being developed as therapeutic agents for Alzheimer's disease, Parkinson's and Schizophrenia, among others.
Suven Life CEO Venkat Jasti said the cognitive disorders for which these drugs would be developed were a $ 30-billion market globally. With this, the biopharma company has a total of 11 granted patents from Europe, eight from Sri Lanka and five from South Korea.
The company said these patents are its exclusive intellectual property, achieved through internal research. Products developed out of these inventions may be outlicensed at different phases of clinical development, it said in a release on Thursday.
